


IMMUNO-ONCOLOGY NETWORK FOR PATIENT ORGANIZATIONS

PATIENT LEADER EDUCATION SUMMIT

Changing Cancer Care in Canada
TOGETHER

EXCHANGE
CANCER CARE INNOVATION
TREATMENT ACCESS
EDUCATION



#CANCERCARECANADA

Changing Cancer Care in Canada. **TOGETHER**

FOREWORD

Immunotherapies are one of the greatest evolutions to emerge in the field of oncology, harnessing the body's own immune system to fight cancer, and providing patients with metastatic and advanced cancer a real chance of survival. Still we are only at the cusp of discovery in understanding the body's potential to attack cancer.

The science is evolving rapidly and the discovery and subsequent introduction of these therapies is changing the way patients live with cancer, the way doctors treat cancer and the ability of our healthcare system to sustain these effective and costly therapies. This is only the beginning.

This Network was set up to not only be a resource for patient advocates to understand how these immuno-oncology therapies work and the role they will play in the treatment of cancer patients, but also to provide an understanding to our decision and policy makers on the value of these new innovative medicines. As larger demands are being placed on our healthcare system, ensuring rapid and appropriate access to this promising class of therapeutics is just one step in a larger battle we will be faced with as patient advocates.

The Network aims to unify the patient voice and empower patient advocates to be fully engaged in this decision making process, in a rapidly evolving oncology landscape. To work together in a spirit of collaboration to find sustainable solutions, will allow the patients we represent to take full advantage of the potential these new immunotherapies provide.

This is your Network, to exchange, to work together toward improving the way cancer care is delivered and organized across Canada, to ensure the equal, timely, appropriate, and affordable access to treatments for cancer patients, and to provide you, the patient advocate, with the tools to fully understand the science and the landscape.

Thank you for joining us. We hope that this education summit is a viable first step in providing you with the information you need in order to carry forward the discussion. Your voice will be heard, and backed by an understanding of the science behind immuno-oncologies as well as the implications that this will mean in the larger framework. We hope that the Network will help to meet the needs of oncology patient advocates in Canada.

DAY ONE PATIENT LEADER EDUCATION SUMMIT

FRIDAY MARCH 31, 2017

BREAKFAST 8.25-8.55

WELCOME 8.55-9.05

Kathy Barnard, President & Founder
Save Your Skin Foundation

LANDSCAPE OF CANCER TODAY AND TOMORROW

Presentation and Q&A 9.05-10.20

Dr. Marcus Butler, Medical Oncologist
Princess Margaret Cancer Centre

Dr. John C. Bell, Senior Scientist, Centre for Innovative
Cancer Research, Ottawa Hospital Research Institute

Monette Greenway, Principal & CO-Founder
Precision Rx Dx

*Moderated by Elizabeth Lye, Scientific Advisor
Lymphoma Canada*

BREAK 10.20-10.30

BUILDING AN IDEAL WORLD FOR IMPROVING PATIENT OUTCOMES IN ONCOLOGY

Panel Discussion and Q&A 10.30-12.00

Dr. Reiner Banken, Senior Fellow
Institute for Clinical and Economic Review (ICER)

Joanne Castonguay, Research Director
Institute for Research on Public Policy (IRPP)

Dr. Femida Gwadry-Sridhar, Founder & CEO
Pulse InfoFrame

Martine Elias, Director Access, Advocacy &
Community Relations
Myeloma Canada

Moderated by Louise Binder, Health Policy Consultant

LUNCH 12.00-13.00

CURRENT STATE OF AFFAIRS

Panel Discussion and Q&A 13.00-14.30

Marie Hotte, Scientific Coordinator, Drug Evaluation
Directorate for Enrolment, Institut national d'excellence
en santé et en services sociaux (INESSS) via video

Imran Ali, Senior Manager
pan-Canadian Pharmaceutical Alliance (pCPA)

Alexandra Chambers, Director
pan-Canadian Oncology Drug review (pCODR)

Heather Logan, Executive Director
Canadian Association of Provincial Cancer
Agencies (CAPCA)

Scott Gavura, Director, Provincial Drug
Reimbursement Cancer Care Ontario (CCO)

*Moderated by Christina Sit, Program Manager
Lung Cancer Canada*

BREAK 14.30-14.45

CHARTING A COURSE: HOW HIV PAVED THE WAY FOR ADVOCACY IN CANCER

Keynote 14.45-15.00

Ryan Peck, Executive Director
HIV & AIDS Legal Clinic Ontario (HALCO)

OPEN FORUM

Highlight of learnings of the day and key takeaways 15.00-16.30

*Moderated by Martine Elias, Director Access,
Advocacy & Community Relations
Myeloma Canada*

COCKTAIL RECEPTION

Official Launch 16.30-18.30

La Maquette
111 King Street

DAY TWO PATIENT LEADER EDUCATION SUMMIT

SATURDAY APRIL 1, 2017

BREAKFAST 8.00-8.30

OPEN FORUM

Environmental Scan 8.30-10.00

A discussion on the current oncology advocacy landscape in Canada to understand what is being done and where the gaps exist.

*Moderated by Sabrina Hanna, Executive Director
Save Your Skin Foundation*

BREAK 10.00-10.15

OPEN FORUM

Roadmapping the Network and Next Steps 10.15-11.50

A discussion on priority setting and tangible areas of improvement in the cancer care delivery and organization eco-system for patient advocates

*Moderated by Sabrina Hanna, Executive Director
Save Your Skin Foundation*

CLOSE

Closing Remarks 11.50-12.00

Barry D. Stein, President
Colorectal Cancer Association of Canada

share the conversation online
#CANCERCARECANADA

SPEAKERS

Dr. Marcus Butler

Medical Oncologist, Princess Margaret Cancer Centre

Marcus Butler is a physician investigator with an interest in the translational development of immune-based therapies for cancer patients. He received his MD from Yale University in New Haven, Connecticut, and trained in Internal Medicine at Johns Hopkins Hospital in Baltimore, Maryland. He then completed a Hematology/Oncology fellowship the Dana-Farber Cancer Institute, Harvard University, in Boston, Massachusetts. After serving on the Dana-Farber staff, he joined the Department of Medical Oncology and Hematology at the Princess Margaret Cancer Centre in 2012 and is an Assistant Professor at the University of Toronto. He cares for patients with melanoma and gynecologic malignancies and is the director of the Princess Margaret Immune Monitoring Laboratory. His work focuses on the development of immunotherapy trials, which include studies, alone and in combination, of immune checkpoint blocking antibodies, immunomodulators, and adoptive cell transfer.

John C. Bell, Ph.D

Senior Scientist, Centre for Innovative Cancer Research, Ottawa Hospital Research Institute Professor, Departments of Medicine and Biochemistry, Microbiology & Immunology, University of Ottawa

Dr. John Bell received his PhD from McMaster University in 1982. The three years that followed, he trained as a post-doctoral fellow at the University of Ottawa and then at the Medical Research Council in London, England. Dr. Bell began his independent research career at McGill University in 1986 and moved to the University of Ottawa, Department of Medicine, in 1989. He is a member of the Center for Cancer Therapeutics at The Ottawa Hospital Cancer Center, a Senior Scientist with the Ottawa Hospital Research Institute and Professor of Medicine at the University of Ottawa. He heads the Canadian Oncolytic Virus Consortium, a Terry Fox funded group from across Canada that is developing virus based cancer therapeutics and is the Director of the Biotherapeutics Program for the Ontario Institute for Cancer Research. He is the Scientific Director of the recently awarded National Centre of Excellence for the development of Biotherapeutics for Cancer Therapy and is a fellow of the Royal Society of Canada.

Monette Greenway, BSc., C. Dir.

Principal & Co-Founder, Precision Rx-Dx Inc.

Monette is Principal & Co-Founder of Precision Rx-Dx Inc. a strategic consultancy focused on Precision Medicine. In collaboration with her partner, Ann Humphreys and their team of senior professionals, they support pharmaceutical and biotechnology companies to build market and organization readiness for the launch of targeted therapeutics and their companion diagnostics. Educated in Genetic Engineering and Biotechnology, Monette's career has centred on the development and successful market adoption of Life Science and diagnostic innovation. Monette has lived and worked internationally with growth mandates in the pharma biomarker development area, and hospital and community lab sectors. With over 25 years of executive experience her past roles include global President/Vice President positions with Thermo Fisher Scientific and Executive Commercial/Government relations' roles with LifeLabs Medical Laboratories, Strategic Diagnostics and Mount Sinai Services.

Dr. Reiner Banken

Senior Fellow Institute for Clinical and Economic Review (ICER)

Dr. Banken started his studies in medicine in Germany. He obtained his medical degree from the Université de Montréal, where he also earned a master's degree in community health. He worked as an emergency physician for five years and as a specialist in public health for 12 years, including serving as the public health director for Québec's Laurentian region. Since 1998 he has been working in Health Technology Assessment, mainly with the different Québec HTA agencies (CETS, AETMIS, INESSS). During the last years he has concentrated on networking, strategic alliances and innovation. Author of several publications and a large number of conferences in the area of public health and health technology assessment, Dr. Banken also serves regularly as a consultant to international organizations such as the World Health Organization (WHO) and the Pan American Health Organization (PAHO). Since October 2015, Dr Banken is working full time as a consultant. Among his clients are different companies in the area of pharmaceuticals, devices and diagnostic tests. Dr Banken is also working with the Boston based Institute for Clinical and Economic Review (ICER). He is continuing his international work as a Senior Research Fellow at the WHO Collaborating Center for Knowledge Translation and Health Technology Assessment in Health Equity, University of Ottawa.

SPEAKERS

Joanne Castonguay

Research Director, Institute for Research on Public Policy (IRPP)

Joanne Castonguay is research director at IRPP managing and associate professor at Pôle santé HEC Montreal. As an economist, she has long been interested in public policy. Before joining the Institute, she was associate vice-president at the Centre interuniversitaire de recherche en analyse des organisations, research director with the Québec Medical Association, adviser at the Fonds de recherche du Québec – Santé, and project director at SECOR Conseil. Her fields of expertise include governance mechanisms of health, research orientation, the transfer of innovation, governance of large projects and socio-political risk management. She has published many articles and reports popularizing these topics, sits on expert panels, and regularly presents at conferences. Over the past decade, several of her publications have contributed to the development of Quebec legislation; for example, the series of reports on the governance of large public infrastructure projects, and the report *Analyse comparative des mécanismes de financement des hôpitaux*. Over the past few years, she has focused on policies promoting the integration of innovation.

Dr. Femida Gwady-Sridhar

Co-Founder and CEO of Pulse Inframe Inc.

Dr. Gwady-Sridhar has her PhD in Research Methodology, Health Economics, McMaster University. She is a pharmacist, epidemiologist and methodologist with over 25 years of experience in clinical trials, disease registries, knowledge translation, health analytics and clinical disease outcomes. She is the Founder of the first knowledge translation health informatics lab in North America in 2006, creating a collaborative ecosystem for interdisciplinary research. In 2008 this facility I-THINK research developed a physical and virtual platform to support multidisciplinary research. The platform has evolved to enable the integration of clinical, imaging and histopathology data. Under her guidance they have commercialized these ventures. More recently, Pulse has collaborated with international funding agencies advancing the requirements for rare disease registries. Collecting relevant and actionable data in rare disease is particularly important and the team at Pulse have addressed relevant questions about data sharing, governance, ontologies and patient reported outcomes- which are key to understand real world evidence.

Dr. Gwady-Sridhar received a career scientist award from CIHR as a New Investigator in knowledge translation- coupled with an operating grant. Over the span of her career she has obtained more than \$10

million in funding for research as a principal investigator or coinvestigator, published in top tier journals and had the privilege of working alongside the best in the world of medicine and business.

She was a founding member of the ISPOR medication adherence group -providing an early glimpse into how to conduct research in adherence. She enjoys collaborating and has been fortunate to do so around the globe across different disciplines and cultures. This experience has resulted in a healthy understanding of the value of collaboration-both as individuals and across the globe.

Martine M. Elias, B.Sc., M.Sc.

Director Access, Advocacy and Community Relations Myeloma Canada

Starting her career in clinical research in the pharmaceutical industry, Martine has dedicated her career to helping patients get access to innovative medical treatments. She is a strong believer in ensuring the patient voice is included in all aspects of health policy decisions. Her role at Myeloma Canada is to develop, lead and execute all advocacy strategies and programs for Myeloma Canada and support the Board of Directors in its goals of shaping access to new therapies and strengthening the Myeloma Canada patient and caregiver community across Canada.

In her most recent position, Martine was the Director, National Patient Engagement Strategy at JANSSEN Inc., with responsibilities for developing and executing an industry-leading national patient engagement strategy. Her main objective was to champion patient advocacy and improve patient access to medications. At the same time, she was also part of an international advocacy team working on a global patient advocacy strategy that engaged with patient groups in various countries around the world. As a recognized industry leader in patient advocacy, Martine was invited to be the Vice-Chair of Rx&D's (now IMC) Stakeholder Strategic Advisory Team. Under her leadership, the committee's role was to advise the Rx&D Board on strategic stakeholder relationship initiatives and best practices.

Martine has a B.Sc. in Biology from the Université de Montréal and a M.Sc. in Marine Mammal Biology from the University of Guelph. A native of Montréal, Martine now resides in Aurora, ON with her husband, three children, three dogs and cat. She also stays active in grassroots politics and is the past president of her local Liberal riding association. She is also Director and Past President of the Estrela Mountain Dog Association of North America.

SPEAKERS

Marie Hotte

Scientific Coordinator, Drug Evaluation Directorate for Enrolment, Institut national d'excellence en santé et en services sociaux (INESSS)

Marie Hotte holds a degree in pharmacy from Université de Laval (1984), hospital pharmacy (1985) and a master's degree in hospital pharmacy (1993) from the Faculty of Pharmacy of the University of Laval (Québec).

She practiced for fifteen years in institutional pharmacy, notably at the CHU de Québec, in various clinical sectors, with a marked interest as well as expertise in diabetology, anticoagulant therapy and take home intravenous antibiotic therapy. During this period, Ms. Hotte was an associate professor and lecturer at the Faculty of Pharmacy at the University of Laval (Québec).

In 2002, she joined the Advisory Council on Pharmacology, which became the Conseil du médicament and later INESSS. She works for the drug evaluation directorate for enrolment, first as a scientific advisor for the clinical aspects of drug listing assessments. Since 2010, she has assumed strategic functions within this department and supports the team in carrying out the work as scientific coordinator.

Imran Ali

Senior Manager, pan-Canadian Pharmaceutical Alliance Office (pCPA)

Imran Ali is the Senior Manager of the pan-Canadian Pharmaceutical Alliance Office and has been in the role since September 2015. From 2012 to 2015, Imran held the position of Senior Manager with the Agreements & Negotiations Unit in the Ontario Ministry of Health and Long-Term Care's Negotiations Branch. In this role, Imran provided leadership and direction for planning, priority setting and negotiation of accountability agreements with individual providers and health care organizations to optimize the Ministry's investment in the health care system valued at over \$11 billion annually.

Recently, Imran provided support for the negotiations process with the Ontario Medical Association (OMA). Prior to this, Imran supported the negotiations of the 2012 Physician Services Agreement with the OMA and lead the coordination of subsequent implementation activities related to the agreement. He also served as the Ministry Co-Chair for the Systems Management Committee, which is responsible for bilateral monitoring and analysis of physician services in Ontario with the OMA. Imran began his career with the Ministry in 2006 with the Primary Health Care Branch where he managed physician services contracts valued in excess of \$50 million annually in the Specialized Models Unit.

Imran graduated with a Masters in Public Health specializing in Health Policy and Management from the University of Alberta's School of Public Health in 2005.

Alex Chambers

Director, pan-Canadian Oncology Drug Review (pCODR)

Before joining CADTH's pCODR in 2014, Ms. Chambers was a Clinical Epidemiologist with Health Quality Ontario and the Ontario Health Technology Advisory Committee (OHTAC). Ms. Chambers holds a Masters degree from McMaster University, and a Bachelor of Science (Hons) degree from the University of Waterloo.

Scott Gavura

Director, Provincial Drug Reimbursement Programs Cancer Care Ontario (CCO)

In this position Scott is responsible for the strategic management of CCO's cancer reimbursement programs. Scott is a registered pharmacist and has a Bachelor of Science in Pharmacy degree and an MBA from the University of Toronto.

Heather Logan

Executive Director, Canadian Association of Provincial Cancer Agencies (CAPCA)

Heather received her BScN and MHS from the University of Toronto. Heather was an Officer in the Canadian Armed Forces, where she served as a military staff and head nurse in oncology, cardiology and step down ICU, and from there held progressively responsible positions leading the national cancer policy and information units at the Canadian Cancer Society National Office and National Cancer Institute of Canada. With a brief but exceptional learning opportunity with one of Canada's innovator pharmaceutical companies mid-way through her term as CAPCA's Executive Director, Heather has lead a series of pan-Canadian initiatives, including a multi-province procurement initiative to drive value and improve efficiency, a first-in-class approach to the safe design of chemotherapy administration, and more recently a pan-Canadian initiative to address cancer drug funding sustainability.

KEYNOTE SPEAKER

Ryan Peck
Executive Director
HIV & AIDS Legal Clinic Ontario (HALCO)

Ryan Peck graduated from the University of Toronto, Faculty of Law in 2000. Since 2007, he has been executive director of the HIV & AIDS Legal Clinic Ontario (HALCO), where he was previously both an articling student and a staff lawyer.

Ryan has worked as a staff lawyer at the Advocacy Centre for the Elderly, and in the Tenant Duty Counsel Program at the Advocacy Centre for Tenants Ontario. He has also served as criminal duty counsel at Toronto's Old City Hall.

Ryan is a member of the Ontario Advisory Committee on HIV/AIDS (which provides HIV-related advice to the Minister of Health and Long-Term Care), chair of the Ontario Working Group on Criminal Law and HIV Exposure, and member of the executive committee of the board of directors of the Canadian HIV/AIDS Legal Network.

NOTES

NOTES

#CANCERCARECANADA

STEERING COMMITTEE

Kathleen Barnard ***President, Save Your Skin Foundation***

In 2003, Kathleen (Kathy) was diagnosed with malignant melanoma, and by 2005 she was informed that her cancer prognosis was terminal. With limited help but unrelenting effort, Kathleen's sons were able to locate a doctor researching a trial immunotherapy drug. Kathleen was given six months to live and it was at this time that she and her family founded Save Your Skin, to ensure that anyone diagnosed with melanoma would not have to travel this journey alone. Her battle with melanoma is ongoing – as long as the disease exists Kathy will ostensibly strive to fight it.

Kathleen prioritizes patient care and support. She was a key player in federal tanning bed legislation for Canada's Youth. As both a melanoma and immunotherapy survivor, Kathleen and her Foundation hope to share the experience and knowledge gained to other patient groups to ensure equal, timely access to new treatments for all cancer patients.

In 2016, Kathy was the recipient of the British Columbia Community Achievement Award for her leadership in addressing and raising awareness around skin cancer issues. She was the first woman to ever coach baseball in the Little League World Series. She is a wife. A mother. And a survivor.

Louise Binder ***Health Policy Consultant***

Louise is a lawyer and health advocate who has been involved in informing the development of health policy and systemic treatment access practices from a patient perspective for more than 20 years. She started her work in this area in the HIV community in the early 1990s after her own diagnosis and before effective treatments were available for HIV.

She co-founded the Canadian Treatment Action Council (CTAC) in 1996, which successfully ensured access to treatments and quality care for people living with HIV by working with the federal and provincial governments and other relevant stakeholders to enhance drug review and approval systems, pricing policies and access to liver transplants for this community. She wrote a paper on universal drug coverage a decade ago while chair of CTAC.

Louise was also chair of the Ontario women's organization Voice of Positive Women for more than a decade, and has been involved in these issues internationally as well. Two years ago, Louise began similar work in the cancer area. She has been recognized by many organizations for her work, including receiving an Honorary Doctorate of Laws from her alma mater, Queen's Law School; the Order of Ontario from the Province of Ontario; and two Queen Elizabeth II medals.

Heather Chappell ***Executive Director, Kidney Cancer Canada***

Heather joined Kidney Cancer Canada as Executive Director in November 2014. Heather comes to us with an impressive and broad background in healthcare ranging from direct clinical services to health services planning and systems analysis. She has a decade of experience working with health charities at both the board and staff level, and is well versed in strategic planning, stakeholder engagement and media relations. Prior to joining Kidney Cancer Canada Heather has held leadership positions with the Canadian Cancer Society where she led diverse portfolios including patient education, international affairs and cancer control policy. Heather holds a MSc degree in health administration from the University of Toronto, and is a Certified Health Executive with the Canadian College of Health Leaders.

Annette Cyr, C.Dir., C.C.P, SHRP ***Chair of the Board, Melanoma Network of Canada***

Ms. Cyr is founder and Chair of the Melanoma Network of Canada as well as a 3 time survivor of melanoma. Annette holds an executive M.B.A, a degree in Business Administration, and professional designation of Chartered Director from McMaster University. In 2012, she was awarded the Queen's Diamond Jubilee medal for service to the community. She is involved in many national and international committees to improve access to clinical trials and treatment for melanoma and skin cancer patients.

Martine Elias ***Director Access, Advocacy & Community Relations,*** ***Myeloma Canada*** ***(see speakers)***

Elizabeth Lye ***Scientific Advisor, Lymphoma Canada***

Elizabeth has extensive academic and research experience in the fields of immunology and cancer biology. She completed her B.Sc. in Immunology at McGill University and carried out her doctoral research at the University of Toronto, where she worked with world-renowned researchers at the Princess Margaret Cancer Centre. More recently, Elizabeth worked as a Medical Editor for the development of educational and support resources for cancer patients and is passionate about helping people build knowledge and confidence to actively participate in their health and wellness.

Christina Sit ***Program Manager, Lung Cancer Canada***

Christina is the Program Manager at Lung Cancer Canada. Lung Cancer Canada is Canada's only national charity focused solely on lung cancer. Christina's portfolio at Lung Cancer Canada includes patient education, awareness, stakeholder relations and

advocacy. She is also responsible for making the patient group submission in support of public funding and access for new treatments and is here today to discuss Lung Cancer Canada's approach to ensuring the patient voice is heard in these decisions.

**Barry D. Stein B. Com., B.C.L., LL.B.
President, Colorectal Cancer Association of Canada**

Barry D. Stein graduated from McGill University and has been a member of the Barreau du Quebec since 1981. An accomplished lawyer and president of the Colorectal Cancer Association of Canada (CCAC), he actively represents the interests of cancer patients and speaks regularly to medical professionals, industry, government, and patient groups both in Canada and internationally covering various aspects of colorectal cancer prevention, treatment and survivorship.

Under Barry's stewardship, the CCAC has developed award winning national awareness and educational programs, support initiatives for patients and their families as well as advocacy on their behalf. Barry has been a key advocate for primary prevention, screening initiatives and equal and timely access to effective treatments to improve outcomes for cancer patients. His efforts have led not only to important changes in health care policy in Canada, but the implementation of provincial colorectal cancer screening programs as well as improved access to drugs and treatments.

He has also helped to create innovative and much needed support programs which led to the establishing of the CCAC's national network of cancer coaches providing peer to peer support to thousands of patients. Today, the support program is part of the CCAC's national cancer coach support network.

Barry is a survivor of metastatic colon cancer. He was diagnosed in 1995 when he was obliged to seek health care outside of Canada to fight his disease. His judgement against RAMQ, obtained in the Superior Court of Quebec in 1999, serves as a leading precedent in Canada for the reimbursement of out of country health care for patients.

**Sabrina Hanna
Executive Director, Save Your Skin Foundation**

Save Your Skin Foundation is a Canadian based patient advocacy group dedicated to skin cancer. Advocating on behalf of patients for access to equal, timely, affordable and appropriate treatment and improving patient outcomes. Sabrina works to bring accountability to process' directly impacting patients' lives and to facilitating education and preventative action programs within the organization.

In 2015, the Save Your Skin Foundation initiated the Immuno-Oncology Network for Patient Organizations in collaboration with other patient advocates to be a resource and tool for all patient advocates in Canada to better understand the quickly changing and evolving landscape in Oncology and the challenges and opportunities it would represent for cancer patients in Canada. Sabrina is the Managing Director of this initiative.

Sabrina also serves as a member of the Innovative Medicines Canada (IMC) Patient Advisory Committee (2017) of the All.Can group based in Europe (2016), of the Melanoma International Patient Advocates Coalition (MI-PAC 2015), and the Global Melanoma Coalition (2015).

Sabrina graduated from Concordia University, in Montreal, with a Bachelor's of Science in Exercise Science. After receiving her B.Sc. she earned a certificate in public relations. Sabrina has dedicated her career to the not-for profit sector, beginning her professional career working in research at the Jewish General Hospital, and prior to joining the team at the Save Your Skin Foundation, worked for the Dean of Libraries at McGill University in Montreal. She has been with the Save Your Skin Foundation since 2014.

THANK
YOU

The Immuno-Oncology Network for Patient Organizations would like to recognize the following people for their contributions to this event

EDUCATION
COMMITTEE

Louise Binder
Annette Cyr
Martine Elias
Christina Sit
Sabrina Hanna

Natalie Richardson
Project Coordinator,
Immuno-Oncology Network
for Patient Organizations

Taylor Kathleen Tomko
Project Coordinator,
Save Your Skin Foundation

share the conversation online

Patient Leader Education Summit-
Change in cancer care starts here
#CANCERCARECANADA

What does the future hold
for the treatment of cancer?
#CANCERCARECANADA

Canadians face delayed access
to innovative medicines
#ImmunoOncology
#CANCERCARECANADA

#ImmunoOncology has great
potential to improve
outcomes for patients with
many types of cancer
#CANCERCARECANADA

Exchange. Cancer Care Innovation.
Treatment Access. Education.
Change in cancer care starts here
#CANCERCARECANADA

Does Canada have adequate
resources for cancer diagnosis
and treatment?
#CANCERCARECANADA

What Value does #ImmunoOncology
bring to the cancer patient, oncologist
and payer?
#CANCERCARECANADA

On average it takes **801** days in
Ontario for new drugs to
become listed after approved
#CANCERCARECANADA

Every 1\$ spent on innovative
medicines is offset by 2\$ in health
savings and economic productivity
gains #ImmunoOncology
#CANCERCARECANADA

Optimizing Canada's cancer care
resources and improving patient
outcomes
#CANCERCARECANADA

Canada scores a "B" grade and
ranks 11th among 16 peer
countries in cancer mortality rates
#CANCERCARECANADA

Cancer costs Canadians \$17.4
billion per year in direct health
care costs, and lost productivity
#CANCERCARECANADA

#CANCERCARECANADA

Patient Leader Education Summit 2017

IMMUNO-ONCOLOGY NETWORK FOR PATIENT ORGANIZATIONS

SPONSORS



Bristol-Myers Squibb Canada

AstraZeneca 

The AstraZeneca logo, with the word "AstraZeneca" in a purple serif font and a yellow and orange stylized DNA double helix icon to the right.

EMD
SERONO

The EMD Serono logo, with "EMD" stacked above "SERONO" in a blue, bold, sans-serif font.

MERCK

The Merck logo, with the word "MERCK" in a bold, black, sans-serif font.

NOVARTIS

The Novartis logo, with the word "NOVARTIS" in a blue, sans-serif font.

abbvie

The AbbVie logo, with the word "abbvie" in a blue, lowercase, sans-serif font.

janssen 

The Janssen logo, with the word "janssen" in a blue, lowercase, sans-serif font and a blue stylized "J" icon to the right.

